Moderna has signed a memorandum of understanding (MoU) with the Government of the Republic of Kenya to build a messenger ribonucleic acid (mRNA) manufacturing facility in the country.

The MoU was signed by the company with assistance from the US Government.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Moderna is establishing this facility in Africa to manufacture up to 500 million vaccines doses per year. 

The company plans to invest up to $500m in this new plant, which is intended to carry out drug substance production for Kenya.

The facility might be extended to incorporate fill/finish as well as packaging expertise at the site. 

Simultaneously, Moderna is developing strategies to permit the new plant to begin to fill doses of its Covid-19 vaccine in Africa by next year, based on the demand.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The mRNA pipeline of the company in its preventive vaccines modality comprises 28 vaccine programmes including those for respiratory viruses, latent viruses and other global public health threats.

Moderna CEO Stéphane Bancel said: “Battling the Covid-19 pandemic over the last two years has provided a reminder of the work that must be done to ensure global health equity.

“Moderna is committed to being a part of the solution and today, we announce another step in this journey – an investment in the Republic of Kenya to build a drug substance mRNA manufacturing facility capable of supplying up to 500 million doses for the African continent each year.” 

In February, Moderna signed a distribution service agreement with Latin American company Adium Pharma, which will facilitate the marketing of the former’s Covid-19 vaccine, Spikevax, in the region. 

According to the agreement, the doses of the vaccine will be supplied in 18 Latin American countries including Brazil, Mexico, Colombia and Argentina.

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
NorthWest EHealth has won three 2025 Pharmaceutical Technology Excellence Awards for Innovation, Safety and Diversity. Explore how its ConneXon platform is transforming SAE reporting and real-time safety oversight, while FARSITE delivers socio-economically inclusive recruitment to boost trial efficiency, data integrity and regulatory-grade representativeness.

Discover the Impact